AM-679 (cannabinoid)

AM-679 structure

AM-679 is a synthetic cannabinoid that acts as a potent and selective agonist for the cannabinoid receptors. It is part of the AM series of cannabinoids developed by Alexandros Makriyannis and his team. AM-679 has been studied for its potential therapeutic applications and its effects on the endocannabinoid system.

Chemical Structure and Properties

AM-679 is chemically classified as a cannabinoid and shares structural similarities with other compounds in the AM series. The specific chemical structure of AM-679 includes a core structure that interacts with the CB1 and CB2 receptors in the endocannabinoid system.

Pharmacology

AM-679 exhibits high affinity for both the CB1 and CB2 receptors. It acts as a full agonist at these receptors, meaning it can fully activate the receptor upon binding. This activation leads to various physiological and psychoactive effects, which are characteristic of cannabinoids.

Therapeutic Potential

Research into AM-679 has indicated potential therapeutic applications, particularly in the areas of pain management, inflammation, and neurological disorders. Its ability to modulate the endocannabinoid system makes it a candidate for further investigation in these fields.

Legal Status

The legal status of AM-679 varies by country. In some jurisdictions, it may be classified as a controlled substance due to its psychoactive properties and potential for abuse. Researchers must adhere to local regulations when studying this compound.

See Also

• Cannabinoid receptor
• Endocannabinoid system
• Synthetic cannabinoids
• Alexandros Makriyannis